-- RBT-101, Radiant's lead oncology program and 4-1BB agonist, demonstrated robust, durable and complete tumor regression without liver toxicity in MC38 colorectal mouse tumor model -- Poster ...
By Daniella Parra Radiant Biotherapeutics presented data from their advancing a breakthrough antibody approach, the Multabody ...
Radiant Biotherapeutics to present new data from lead oncology programme at SITC 2025 annual meeting: Toronto Thursday, November 6, 2025, 18:00 Hrs [IST] Radiant Biotherapeutics, ...
Radiant Biotherapeutics, a biotechnology company committed to advancing a breakthrough antibody approach, the Multabody™, for a broad range of therapeutic areas, including cancer and infectious ...